

This article was downloaded by: [Malmo Hogskola]

On: 19 December 2011, At: 23:34

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/ganp20>

Lignans from *Schisandra lancifolia*

Jing-Jiao Xue^{a b}, Jing-Li Cao^{a b}, Guang-Yu Yang^{a c}, Jian-Xin Pu^a, Han-Dong Sun^a, Qiu-Fen Hu^b & Wei-Lie Xiao^a

^a State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650204, China

^b School of Chemistry and Biotechnology, Yunnan Nationalities University, Kunming, 650031, China

^c Key Laboratory of Tobacco Chemistry of Yunnan Province, Yunnan Academy of Tobacco Science, Kunming, 650106, China

Available online: 25 May 2011

To cite this article: Jing-Jiao Xue, Jing-Li Cao, Guang-Yu Yang, Jian-Xin Pu, Han-Dong Sun, Qiu-Fen Hu & Wei-Lie Xiao (2011): Lignans from *Schisandra lancifolia*, *Journal of Asian Natural Products Research*, 13:06, 492-497

To link to this article: <http://dx.doi.org/10.1080/10286020.2011.570949>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Lignans from *Schisandra lancifolia*

Jing-Jiao Xue^{ab}, Jing-Li Cao^{ab}, Guang-Yu Yang^{ac}, Jian-Xin Pu^a, Han-Dong Sun^a,
Qiu-Fen Hu^{b*} and Wei-Lie Xiao^{a*}

^aState Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204, China; ^bSchool of Chemistry and Biotechnology, Yunnan Nationalities University, Kunming 650031, China; ^cKey Laboratory of Tobacco Chemistry of Yunnan Province, Yunnan Academy of Tobacco Science, Kunming 650106, China

Two new neolignans, schilancifolignans D and E (**1** and **2**), together with eight known ones, were isolated from the leaves and stems of *Schisandra lancifolia*. The structures of **1** and **2** were elucidated by spectroscopic methods, including extensive 1D and 2D NMR techniques. Compounds **1** and **2** were tested for their anti-HIV-1 activities and cytotoxicity. Both showed significant potential cytotoxic ability and weak anti-HIV-1 activities.

Keywords: *Schisandra lancifolia*; lignans; schilancifolignans D and E; anti-HIV-1 activities; cytotoxicity

1. Introduction

Plants of the economically and medicinally important genus *Schisandra* (Schisandraceae) are known to be a rich source of lignans, lanostane, and cycloartane triterpenes, which have been found to possess various beneficial pharmacological effects [1,2]. Since 2003, the systematical chemical investigation of the genus *Schisandra* conducted by our group led to the discovery of a series of novel nortriterpenoids with a diversity of highly oxygenated structures biogenetically related to cycloartane, some of which showed promising anti-HIV-1 activities with low toxicities [2–5]. *Schisandra lancifolia*, one species of this genus, is a climbing plant mainly distributed in Mainland of China [6]. In our previous work, some new highly oxygenated nortriterpenoids and dibenzocyclooctadiene lignans were isolated from this plant [7–9]. As a part of our search for bioactive materials, the phytochemical

study of an EtOAc extract of *S. lancifolia* led to the isolation of two neolignans (**1** and **2**), along with eight known compounds (**3**–**10**). The structural elucidation of compounds **1** and **2** and the evaluation of their anti-HIV-1 activities and cytotoxicity in several cancer cell lines are reported in this study.

2. Results and discussion

A 70% aq. acetone extract prepared from the leaves and stems of *S. lancifolia* was partitioned between EtOAc and H₂O. The EtOAc layer was subjected repeatedly to column chromatography on silica gel, Sephadex LH-20, RP-18 and Preparative HPLC to afford compounds **1**–**10** (Figure 1), including two new neolignans named schilancifolignans D and E (**1** and **2**), together with eight known lignans, pregomisin (**3**) [10], 4-[(2*R*,3*S*)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-2-methoxy-phenol (**4**) [11], 4,4'-(2*R*,3*S*)-2,3-

*Corresponding authors. Email: huqiufena@yahoo.com.cn; xwl@mail.kib.ac.cn




Figure 1. The structures of compounds 1–10.

dimethylbutane-1,4-diyl)bis(1,2-dimethoxybenzene) (**5**) [12], prinsepiol (**6**) [13], dehydrodiconiferyl alcohol (**7**) [14], austrobailignan (**8**) [15], dimethyltetrahydrofuroguaiacin (**9**) [16], and wik-stromol (**10**) [17].

Compound **1** was obtained as a yellow gum. Its molecular formula was determined as C₂₃H₃₀O₇ by HR-ESI-MS at *m/z* 441.1895 [M + Na]⁺. Its ¹H and ¹³C NMR spectra (Table 1) showed signals of 30 protons and 23 carbons, respectively, corresponding to two aromatic rings with four aromatic protons, two methyl groups, four methoxyl groups, one methylenedioxy group, one oxidated methylene group, and three methine signals. Strong absorption bands accounting for hydroxy (3340 cm⁻¹) and aromatic groups (1610, 1595, 1518, and 1460 cm⁻¹) could also be

observed in its IR spectrum. The UV spectrum of **1** showed absorption maxima at 282 and 205 nm, which confirmed the existence of the aromatic functions. The HMBC spectrum of compound **1** showed cross-peaks between H-7 (δ_H 3.99, d, *J* = 11.4 Hz) and carbons of both aromatic rings, C-2 (δ_C 104.6), C-6 (δ_C 107.2), C-2' (δ_C 106.6), C-6' (δ_C 106.6), whereas there was no correlation between H-9' and any aromatic carbon, which indicated that the two aromatic rings were linked to the same carbon C-7. The ¹H–¹H COSY correlations of H-7/H-8/H-8'/H-9', H-8/H-9, and H-8'/H-7, together with HMBC correlations (Figure 2) of H-7 (δ_H 3.99, d, *J* = 11.4 Hz) with C-8 (δ_C 36.7), C-9 (δ_C 12.2), and C-8' (δ_C 36.6), and of H-7' (δ_H 0.94, d, *J* = 7.1 Hz) with C-8' (δ_C 36.6), C-9' (δ_C 66.8), C-8 (δ_C 36.7),

Table 1. ^1H and ^{13}C NMR spectral data of compounds **1** and **2** (δ in ppm, data obtained in pyridine- d_5).

No.	1		2	
	^{13}C	^1H	^{13}C	^1H
1	137.2, s		137.5, s	
2	104.6, d	6.46, s	104.9, d	6.47, s
3	148.5, s		148.8, s	
4	133.9, s		133.8, s	
5	146.1, s		146.6, s	
6	107.2, d	6.35, s	107.5, d	6.37, s
7	56.6, d	3.99, d, $J = 11.4$ Hz	57.5, d	4.07, d, $J = 11.6$ Hz
8	36.7, d	3.19–3.22, m	39.6, d	3.32–3.36, m
9	12.2, q	0.91, d, $J = 6.9$ Hz	15.0, q	1.23, d, $J = 6.7$ Hz
10	101.3, t	5.87, s	101.2, t	5.83, s
1'	138.2, s		138.3, s	
2'	106.6, d	6.11, d, $J = 1.9$ Hz	106.1, d	6.15, d, $J = 1.8$ Hz
3'	152.2, s		152.5, s	
4'	140.2, s		140.0, s	
5'	152.2, s		152.5, s	
6'	106.6, d	6.11, d, $J = 1.9$ Hz	106.1, d	6.15, d, $J = 1.8$ Hz
7'	10.2, q	0.94, d, $J = 7.1$ Hz	20.3, q	0.99, d, $J = 6.8$ Hz
8'	36.6, d	2.28–2.34, m	28.5, d	2.31–2.34, m
9 α	66.8, t	3.79, d, $J = 13.6$ Hz	20.0, q	1.02, d, $J = 6.8$ Hz
9 β		3.93, dd, $J = 11.2, 6.6$ Hz		
OMe-5	55.9, q	3.73, s	56.0, q	3.83, s
OMe-3'	55.7, q	3.70, s	55.8, q	3.79, s
OMe-4'	60.7, q	3.72, s	60.8, q	3.81, s
OMe-5'	55.7, q	3.70, s	55.8, q	3.79, s
OH-9'		5.01 br s		

suggested the existence of a $\text{OH}-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)-\text{CH}$ structural unit in **1**. The ^1H and ^{13}C NMR spectra of **1** are similar to those of 4,4-di(4-hydroxy-3-methoxyphenyl)-2,3-dimethylbutanol [18]. The obvious differences are the chemical shift of aromatic rings, and the substituent groups on aromatic rings. The HMBC correlations of H-10 (δ_{H} 5.87, s) with C-3 (δ_{C} 148.5) and C-4 (δ_{C} 133.9) indicated




Figure 2. Selected HMBC (\rightarrow) and $^1\text{H}-^1\text{H}$ COSY (\dashrightarrow) correlations of **1**.

that the methylenedioxy group should be located at C-3 and C-4. The HMBC correlations of four methoxyl groups with C-5, C-3', C-4', and C-5' indicated that four methoxyl groups should be located at C-5, C-3', C-4', and C-5', respectively. As the C–C bonds can rotate randomly, the relative configuration of compound **1** could not be determined on the basis of ROESY spectrum. Thus, the structure of compound **1** was determined as shown in Figure 1, and this compound is named as schilancifolignan D.

Compound **2** was also obtained as a yellow gum. It was assigned the molecular formula $\text{C}_{23}\text{H}_{30}\text{O}_6$ by its HR-ESI-MS at m/z 425.1932 $[\text{M} + \text{Na}]^+$. Its ^1H and ^{13}C NMR spectra showed signals of 30 protons and 23 carbons, respectively, corresponding to two aromatic rings with four aromatic protons, three methyl groups,

four methoxyl groups, one methylene-dioxy group, and three methine signals. The ^1H and ^{13}C NMR spectra of **2** are similar to those of compound **1**. Analysis of the ^1H and ^{13}C NMR spectral data of **2** with those of **1** suggested that the difference was that an oxidated methylene group (C-9) in **1** was substituted by a methyl group in **2**, which was supported by the disappearance of the signal of an oxidated methylene group and the appearance of a methyl group at δ 1.23 (d, $J = 6.7$ Hz) in **2**. Thus, the planar structure of compound **2** was determined as shown in Figure 1, and this compound was named as schilancifolignan E.

3. Experimental

3.1 General experimental procedures

Optical rotations were measured with a Horiba SEPA-300 polarimeter. UV spectra were obtained using a Shimadzu UV-2401A spectrophotometer. A Tenor 27 spectrophotometer was used for scanning IR spectroscopy with KBr pellets. 1D and 2D NMR spectra were recorded on DRX-500 spectrometer with TMS as internal standard. Unless otherwise specified, chemical shifts (δ) were expressed in ppm with reference to the solvent signals. HR-ESI-MS was performed on an API QSTAR time-of-flight spectrometer and a VG Autospec-3000 spectrometer, respectively. Preparative HPLC was performed on a Shimadzu LC-8A preparative liquid chromatograph with a ZORBAX PrepHT GF (21.2 mm \times 25 cm, 7 μm) column or a Venusil MP C₁₈ (20 mm \times 25 cm, 5 μm) column. Column chromatography was performed with silica gel (200–300 mesh, Qing-Dao Marine Chemical, Inc., Qingdao, China), Lichroprep RP-18 gel (40–63 μm , Merck, Darmstadt, Germany), and MCI gel (75–150 μm , Mitsubishi Chemical Corporation, Tokyo, Japan). The fractions were monitored by TLC, and spots were visualized by heating silica gel plates sprayed with 5% H_2SO_4 in EtOH.

3.2 Plant material

The leaves and stems of *S. lancifolia* were collected in Erlang Mountain area of Sichuan Province, China, in September 2007. The identification of plant material was verified by Prof. Xi-Wen Li. A voucher specimen (KIB-07-09-28) has been deposited in the State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, China.

3.3 Extraction and isolation

The air-dried and powdered leaves and stems of *S. lancifolia* (3.2 kg) were extracted four times with 70% aqueous Me_2CO (4 \times 3.5 liters) at room temperature and filtered to yield a filtrate, which was successively evaporated under reduced pressure and partitioned with EtOAc (3 \times 4 liters). The EtOAc partition (158 g) was applied to silica gel (200–300 mesh) column chromatography eluting with a CHCl_3 –MeOH gradient system (20:1, 9:1, 8:2, 7:3, 6:4, and 5:5) to give six fractions A–F. The separation of fraction B (9:1, 18.9 g) by silica gel column chromatography eluted with petroleum ether–acetone (9:1–1:2) yielded mixtures B1–B6. Fraction B2 (8:2, 3.25 g) was subjected to silica gel column chromatography using petroleum ether–acetone (8:2) and preparative HPLC (68% MeOH– H_2O , flow rate 12 ml/min) to give compounds **2** (5.4 mg), **5** (25.2 mg), **8** (18.5 mg), and **9** (35.2 mg). Fraction B3 (7:3, 1.86 g) was subjected to silica gel column chromatography eluting with petroleum ether–acetone (7:3) and then run on preparative HPLC (63% MeOH– H_2O , flow rate 12 ml/min) to yield compounds **1** (4.2 mg), **4** (26.2 mg), and **7** (19.5 mg). Fraction B4 (6:4, 1.24 g) was subjected to silica gel column chromatography eluting with petroleum ether–acetone (6:4) and then run on preparative HPLC (58% MeOH– H_2O , flow rate 12 ml/min) to give compounds **3** (6.8 mg), **6** (13.4 mg), and **10** (11.6 mg).

Table 2. Cytotoxicities of schilancifolignans D and E.

Compounds	Cell lines			
	HL-60	HepG2	KB	MDA-MB-231
1	4.15	12.2	8.21	18.4
2	5.21	7.26	12.4	8.57
Camptothecin	1.18	0.62	1.26	1.87

Notes: Data are IC₅₀ values in $\mu\text{mol/l}$. For a compound to be deemed effective, an IC₅₀ value < 100 $\mu\text{mol/l}$ is required. Camptothecin was used as a positive control. HL-60, human acute promyelocytic leukemia; Hep-G2, human hepatocellular carcinoma; KB, human oropharyngeal epidermoid carcinoma; MDA-MB-231, human breast cancer cells.

3.4 Anti-HIV-1 assay

The cytotoxicity assay against C8166 cells (CC₅₀) was assessed using the MTT method and anti-HIV-1 activity was evaluated by the inhibition assay for the cytopathic effects of HIV-1 (EC₅₀) [19]. Schilancifolignan D shows anti-HIV-1 activity with EC₅₀ 3.62 $\mu\text{g/ml}$, CC₅₀ 56.6 $\mu\text{g/ml}$, and therapeutic index (TI) 15.6. Schilancifolignan E shows anti-HIV-1 activity with EC₅₀ 2.87 $\mu\text{g/ml}$, CC₅₀ 51.4 $\mu\text{g/ml}$, and TI 17.9.

3.5 Cytotoxicity assays

The cytotoxicity tests for the isolates were performed using a previously reported procedure [20]. All treatments were performed in triplicate. In the MTT assay, IC₅₀ was defined as the concentration of the test compound resulting in a 50% reduction of absorbance compared with untreated cells. The cytotoxic ability against HL-60, Hep-G2, KB and MDA-MB-231 tumor cell lines by MTT-assay (with camptothecin as the positive control) was shown in Table 2.

3.5.1 Schilancifolignan D (1)

Obtained as a pale yellow amorphous solid; $[\alpha]_{\text{D}}^{15.8} + 8.4$ ($c = 0.18$, MeOH); UV (MeOH) λ_{max} (log ϵ) 326 (2.58), 282 (4.15), 205 (4.95) nm; IR (KBr) ν_{max} 3340, 2962, 2932, 2875, 2834, 1610, 1595, 1518, 1460, 1415, 1378, 1330, 1267, 1240, 1228, 1185, 1143, 1026, 972, and 823 cm^{-1} ; ¹H and ¹³C NMR spectral data (Table 1);

positive ESI-MS m/z 441 $[\text{M} + \text{Na}]^+$; HR-ESI-MS: m/z 441.1895 $[\text{M} + \text{Na}]^+$ (calcd for C₂₃H₃₀O₇Na, 441.1889).

3.5.2 Schilancifolignan E (2)

Obtained as a yellow gum; $[\alpha]_{\text{D}}^{21.9} + 9.7$ ($c = 0.15$, MeOH); UV (MeOH) λ_{max} (log ϵ) 326 (2.65), 282 (4.11), 205 (5.01) nm; IR (KBr) ν_{max} 2974, 2945, 2880, 2842, 1618, 1595, 1521, 1460, 1426, 1375, 1257, 1264, 1148, 1022, 976, and 825 cm^{-1} ; ¹H and ¹³C NMR spectral data (Table 1); positive ESI-MS m/z 425 $[\text{M} + \text{Na}]^+$; HR-ESI-MS (positive ion mode): m/z 425.1932 $[\text{M} + \text{Na}]^+$ (calcd for C₂₃H₃₀O₆Na, 425.1940).

Acknowledgements

This project was supported financially by the National Nature Science Foundation of China (Nos 30830115 and 20802082), projects from the Chinese Academy of Sciences (Nos KSCX2-EW-Q-10 and KSCX1-YW-R-24), 973 Program (Nos 2009CB522303, 2009CB522306, and 2009CB940900), the Scientific and Technological projects of China (No. 2009ZX09501-029), the Yong Academic and Technical Leader Rising Foundation of Yunnan Province (No. 2006PY01-47), and the Natural Science Foundation of Yunnan Province (Nos 2005XY04 and 2006B0042Q).

References

- [1] J.B. Chang, J. Reiner, and J.X. Xie, *Chem. Rev.* **105**, 4581 (2005).
- [2] M. Cosentino and K.H. Lee, *Bioorg. Med. Chem.* **5**, 1715 (1997).

- [3] J.X. Pu, R.T. Li, W.L. Xiao, N.B. Gong, S.X. Huang, Y. Lu, Q.T. Zheng, L.G. Lou, and H.D. Sun, *Tetrahedron* **62**, 6073 (2006).
- [4] W.L. Xiao, Y.Q. Gong, R.R. Wang, Z.Y. Weng, X. Luo, X.N. Li, G.Y. Yang, and H.D. Sun, *J. Nat. Prod.* **72**, 1678 (2009).
- [5] C. Lei, S.X. Huang, J.J. Chen, L.B. Yang, W.L. Xiao, Y.L. Chang, and H.D. Sun, *J. Nat. Prod.* **71**, 1228 (2008).
- [6] Editorial Committee of Flora of China. *Flora Yunnanica* (Science Press, Beijing, 2000), Vol. 11, p. 22.
- [7] W.L. Xiao, S.X. Huang, L. Zhang, R.R. Tian, L. Wu, X.L. Li, J.X. Pu, and H.D. Sun, *J. Nat. Prod.* **69**, 650 (2006).
- [8] R.T. Li, W. Xiang, S.H. Li, Z.W. Lin, and H.D. Sun, *J. Nat. Prod.* **67**, 94 (2004).
- [9] W.L. Xiao, S.X. Huang, R.R. Wang, J.L. Zhong, X.M. Gao, F. He, J.X. Pu, and Q.T. Zheng, *Phytochemistry* **69**, 2862 (2008).
- [10] Y. Ikeya, H. Taguchi, I. Yosioka, and H. Kobayashi, *Chem. Pharm. Bull.* **26**, 682 (1978).
- [11] G. Li, H.K. Ju, H.W. Chang, Y.D. Jahng, S.H. Lee, and J.K. Son, *Biol. Pharm. Bull.* **26**, 1039 (2003).
- [12] E.K. Nemethy, R. Lago, D. Hawkins, and M. Calvin, *Phytochemistry* **25**, 959 (1986).
- [13] S.B. Kilidhar, M.R. Parthasarathy, and P. Sharma, *Phytochemistry* **21**, 796 (1982).
- [14] H. Kasahara, Y. Jiao, D.L. Bedgar, S.J. Kim, A.M. Patten, Z.Q. Xia, L.B. Davin, and N.G. Lewis, *Phytochemistry* **67**, 1765 (2006).
- [15] S.T. Murphy, E. Ritchie, and W.C. Taylor, *Aust. J. Chem.* **28**, 81 (1975).
- [16] Y.H. Gong and L.S. Ding, *¹³C-NMR Analysis of Natural Products*, 2nd ed. (Yunan Science and Technology Press, Kunming, 2006), p. 616.
- [17] S. Nishebe, S. Hisada, and I. Inagaki, *Phytochemistry* **10**, 2231 (1971).
- [18] L.J. Xu, F. Huang, S.B. Chen, L.N. Li, S.L. Chen, and P.G. Xiao, *J. Integr. Plant Biol.* **48**, 1493 (2006).
- [19] J.H. Wang, S.C. Tam, H. Huang, D.Y. Yang, Y.Y. Wang, and Y.T. Zheng, *Biochem. Biophys. Res. Commun.* **317**, 965 (2004).
- [20] T. Mosmann, *J. Immunol. Methods* **65**, 55 (1983).